Company
Every investor coverage indicates participated in a round AdAlta raised.
Companies AdAlta acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming AdAlta. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
AdAlta, an ASX-listed biotech, has completed a $2.5 million placement to progress its CAR-T cancer treatment toward trials, with funds earmarked for US regulatory engagement and a domestic manufacturing transfer via Cell Therapies.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.